Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
11,191 total articles
Sterling Infrastructure sits squarely in the AI/data-center supply chain after a rapid re-rating. Strong top-line momentum, a $5.15B backlog and raised guidance argue for continued upside, but the stock trades at a steep multiple. This trade idea targets a mid-term swing entry on a controlled pullback with clear stop and target levels.
Applied Optoelectronics (AAOI) is benefiting from hyperscaler demand for 800G and 1.6T optical modules. Strong tape of volume, improving technicals and continued product-led scarcity support a tactical long. The valuation is rich, so keep position sizing prudent and use a clearly defined stop.
Nebius Group (NBIS) is trading after an all-time high on heavyweight endorsements and multibillion customer commitments. The company is executing an aggressive capacity build to capture AI cloud demand, and recent top-line momentum is explosive. This trade idea outlines a long-biased plan with entry, stop and target that balances the structural gro…
Western Digital has crossed a profitability inflection with 50%+ gross margins and strong free cash flow. The stock is expensive by traditional multiples but momentum and long-term contracts with cloud customers leave room for upside. This is a tactical long trade for swing traders who want exposure to the AI-driven storage narrative while managing…
Nano Labs (NA) trades at roughly $59M market cap, a trailing P/E of ~2.8 and PB ~0.58. The company designs high-performance chips and distributed computing solutions; management has pivoted capital into crypto reserves while cutting operating expenses. Recent CEO purchases, a North America AI data center MOU and new hardware launches create near-te…
Vistra is a cash-generative independent power producer with large-scale generation, growing exposure to data-center and AI load through long-term contracts, and an improving valuation lens versus idiosyncratic 2026 sell-offs. Strong free cash flow, a sizeable market cap, and recent corporate actions make a buy-with-a-plan trade attractive for patie…
CoreWeave is trading materially below its 52-week high after a volatile stretch. With revenue growth well into triple digits, a $99.4B backlog, and an enlarged Nvidia stake validating its strategic position in AI infrastructure, CoreWeave looks like a compelling core long for investors willing to accept elevated balance-sheet and concentration risk…
Celestica (CLS) has sharply re-rated as its Advanced Technology and Connectivity segments scale into AI, cloud networking and aerospace. Recent results showed 53% revenue growth and raised FY26 guidance to $19.0B and $10.15 adjusted EPS. Momentum is strong, but valuation is rich. This trade idea buys a measured pullback for a long-term (180 trading…
Willis Towers Watson (WTW) sold off after Q1 margin weakness and tepid organic growth, but the pullback looks overdone. At $256.41, WTW trades at ~15x EPS with $1.57B in free cash flow and a manageable debt load. This trade idea targets a rebound to $320 over the next 180 trading days, using a logical stop at the recent 52-week low to protect downs…
Carvana just saw used-car pricing pressure flip into a tailwind. With headline used-car prices at a two-year high, improving margins, strong free cash flow, and a crowded short book, CVNA offers an asymmetric risk-reward for disciplined longs. Trade plan below targets a move back toward the post-split highs while respecting the company’s elevated v…
MannKind (MNKD) just cleared a major commercial milestone with FDA approval of Afrezza for children and adolescents 6 and older. Q1 2026 revenue momentum (15% YoY to $90.2M) and multiple upcoming presentations create a near-term re-rating opportunity. This trade idea lays out an entry, stop, and target with a clear horizon and risk framework tied t…
Surge Energy is a levered play on a sustained oil-price recovery. Operational leverage, tight cost structure, and disciplined capital allocation make this an actionable long with a clear risk-managed entry at $2.40, stop at $1.80 and primary target at $4.00 over the next 180 trading days.
Madrigal Pharmaceuticals (MDGL) is a commercial-stage liver-focused biotech with an FDA- and EC-approved therapy (Rezdiffra) and a growing combination-ready pipeline. The balance sheet, recent licensing deals and an oversold technical setup create an asymmetric trade: entry at $452.76, stop at $360.00, target $800.00 over a long-term window (180 tr…
Sable Offshore plunged after an investor call highlighted near-term execution risk. We think the reaction priced in more downside than fundamentals support. This trade idea outlines a mid-term (45 trading days) long with clear entry, stop and target, and explains the drivers, catalysts and risks.
Chili's is delivering outsized traffic and margin recovery, driving free cash flow growth and making Brinker look cheap on conventional metrics. That said, the stock has already run, short interest is nontrivial, and macro or cost shocks could trim upside. I favor a measured long trade over a mid-term (45 trading days) horizon: enter near $138.20, …
Aercap (AER) is trading at a single-digit P/E and below its 52-week high despite renewed commercial aircraft demand and material fleet-level deals. With a market cap near $22.4B, a 52-week range of $105.65-$154.94, and improving orderflow, the risk/reward favors a disciplined long over the next 45 trading days if you control downside with a hard st…
Games Workshop benefits from a uniquely devoted customer base that underpins recurring product cycles, premium pricing, and cross-media expansion. We outline a long-term long trade with entry at $40.00, a $52.00 target and a $33.00 stop loss, explain the business drivers, catalysts and valuation logic, and flag the key risks that could derail the t…
Grupo Aval is trading near $4.95 with a market cap of about $5.58B, a P/E of 14.1 and a P/B of 1.26. Technical momentum (RSI ~60, bullish MACD) and elevated short activity set up a mid-term (45 trading days) trade that targets a move above the 52-week high. Entry: $4.95, Stop: $4.50, Target: $5.50.
Talen Energy (TLN) has seen a fresh repricing after regulatory clearances for a three-plant acquisition and the earlier pricing of $4 billion in senior notes. The fundamentals — high leverage, elevated valuation multiples, and a large near-term capacity add financed with long-dated debt — leave the stock vulnerable to a mean-reversion move. This tr…
Riley Exploration Permian reported operational momentum into Q1, reaffirmed capital returns with a $0.40 quarterly dividend, and sits on attractive valuation metrics (EV/EBITDA ~4.2, P/E ~12.5). For traders, a disciplined long with a tight stop below near-term support offers an asymmetric setup over the next 45 trading days.
Alphabet's $80 billion capital raise rattled the stock and broke short-term technical support, but the deal - including a $10 billion commitment from Berkshire Hathaway - shores up compute capacity and balance-sheet optionality. With Google Cloud growth still accelerating and free cash flow north of $64 billion, a disciplined long here offers asymm…
Neste is one of the few industrial-scale players with integrated refining, feedstock procurement and distribution in renewable diesel and sustainable aviation fuel (SAF). This trade idea argues for a long exposure based on accelerating SAF demand, capacity additions, and favorable regulatory tailwinds. Entry, target and stop are specified with a lo…
Alphabet dropped sharply after an $80 billion capital raise was announced, but Berkshire Hathaway's $10 billion direct placement and the company's strong cash flow, profitable core business and hyper-growth Cloud backlog argue that the market overreacted. This is a tactical long idea for a 45-trading-day swing — entry $365.00, stop $345.00, target …
Arm just hit a fresh 52-week high as AI customers stack into its energy-efficient CPU designs. The combination of recurring royalty economics, accelerating design wins (Oracle, ByteDance, Nvidia partnerships) and still-early data-center adoption argues for more upside. This is a momentum-plus-fundamentals trade: enter at current levels with a disci…
C4 Therapeutics is advancing cemsidomide as a potential best‑in‑class IKZF1/3 degrader for multiple myeloma. With Phase 2 (MOMENTUM) underway and a clear recommended Phase 2 dose, recent program milestones plus positive sentiment around the degrader class support a swing trade. We lay out an actionable buy: entry $4.32, stop $3.30, target $6.00 ove…
